Torrent House
Off. Ashram Road
Ahmedabad 380009
India
91 79 2659 9000
https://www.torrentpharma.com
Sector(s): Healthcare
Industry: Drug Manufacturers—Specialty & Generic
Full Time Employees: 12,703
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Samir Uttamlal Mehta | Exec. Chairman & MD | 200.04M | N/A | 1964 |
Mr. Jinesh Shah B.Sc., MBA | Exec. Director of Operations & Whole Time Director | 58.12M | N/A | 1977 |
Mr. Sudhir Menon CA, CWA | Exec. Director of Fin. & CFO | N/A | N/A | 1972 |
Mr. Chintan Trivedi | Company Sec. & Compliance Officer | N/A | N/A | N/A |
Mr. Abdullah Salam Said Al Abri | Chief Customer Service Officer | N/A | N/A | N/A |
Mr. R. Chandrashekhar Inter CA | VP of Procurement | N/A | N/A | 1969 |
Jaydip Bhatt | VP of Human Resource | N/A | N/A | 1953 |
H. L. Guttikar B.E., MMS | VP of Projects | N/A | N/A | 1963 |
Ashish Hajarnish M.Pharm | VP of Works | N/A | N/A | 1968 |
Hasmukh Patel B.Pharm, M.Pharm. | VP of Works | N/A | N/A | 1968 |
Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, and marketing of generic pharmaceutical formulations in India, the United States, Germany, Brazil, and internationally. It offers products in various therapeutic areas, including cardiovascular, central nervous system, gastrointestinal, women healthcare, diabetology, pain management, gynecology, oncology, and anti-infective, as well as provides vitamins, minerals, and nutrients. The company also provides contract manufacturing services. It has licensing collaborations of Baricitinib, Molnupiravir, and Paxlovid for its Covid portfolio. Torrent Pharmaceuticals Limited was formerly known as Trinity Laboratories and changed its name to Torrent Pharmaceuticals Limited in 1971. The company was founded in 1959 and is based in Ahmedabad, India. Torrent Pharmaceuticals Limited is a subsidiary of Torrent Investments Private Limited.
Torrent Pharmaceuticals Limited’s ISS Governance QualityScore as of October 1, 2022 is 8. The pillar scores are Audit: 4; Board: 8; Shareholder Rights: 9; Compensation: 1.